Company Interview / Amplia one step closer in the fight against pancreatic cancer

Dr Chris Burns of Amplia Therapeutics (ASX: ATX) announces US ethics approval for a phase two trial on pancreatic cancer treatment. Amplia's drug, combined with standard chemotherapy, aims for improved patient outcomes. Trials will commence in the US and Australia shortly.

Chris highlights promising earlier results from the Australian Accent trial, noting two complete responses in metastatic cases. Amplia's (ASX: ATX) drug makes fibrotic scar tissue permeable, enhancing chemotherapy's effectiveness against resilient cancers like pancreatic and ovarian.

Funding is secure with $10 million available for trials, extending potential partnerships. Focus remains on pancreatic cancer, with expanding interests into ovarian and other fibrotic cancers.